An update from BioVie ( (BIVI) ) is now available.
BioVie Inc., a clinical-stage company, has announced a registered direct offering and concurrent private placement, pricing 2,667,000 shares of its common stock at $2.25 per share, with unregistered warrants allowing purchase of additional shares at $2.12 each. This deal, facilitated by ThinkEquity, aims to raise approximately $6 million before expenses, with proceeds earmarked for working capital and corporate purposes. The offering is set to close around October 24, 2024, pending customary conditions.
See more insights into BIVI stock on TipRanks’ Stock Analysis page.
